登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Effect of Xuesaitong Soft Capsules on Major Risk Factors in Patients With Coronary Heart Disease
ClinicalTrials.gov 上登记的一项冠心病开放试验。牵头方不是本站收录的医院;本站收录的 2 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 2
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06425120,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 4
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(4 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Acute coronary syndrome occurred or received percutaneous coronary intervention therapy within the past 3 months
排除标准第 2 条
Progressive neuromuscular disease, or creatine kinase (CK) levels > 3 times the normal upper limit (ULN)
排除标准第 7 条
Active liver disease, or alanine aminotransferase (ALT) levels > 3 times the upper limit of normal (ULN)
排除标准第 16 条
Chronic kidney disease, or estimated glomerular filtration rate (eGFR) <60ml/ (min×1.73m2)
排除标准第 17 条
Pregnancy or planned pregnancy, or breastfeeding
排除标准第 18 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);日常活动能力;影像与可测量病灶;试验排除的其他疾病。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06425120,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Age ≥18 years old Chronic coronary artery disease: meet any of the following conditions, and the condition is stable for at least 3 months: History of myocardial infarction Have received coronary interventional therapy There are symptoms of myocardial ischemia (such as chest pain) and objective evidence (stress electrocardiogram or stress myocardial perfusion imaging indicated myocardial ischemia or coronary artery stenosis ≥50% ) High-sensitivity C-reactive protein ≥2mg/L Currently taking moderate or above intensity statins lipid-lowering drugs Currently taking antiplatelet drugs Sign informed consent排除标准:Exclusion Criteria:
Patients fulfilling any of the following criteria are not eligible for inclusion in this trial: Acute coronary syndrome occurred or received percutaneous coronary intervention therapy within the past 3 months Previously received coronary artery bypass grafting Stroke occurred within the previous 3 months Symptomatic heart failure (HF) in the past, or documented left ventricular ejection fraction < 35% Revascularization or surgical procedures are planned within the next 3 months Progressive neuromuscular disease, or creatine kinase (CK) levels > 3 times the normal upper limit (ULN) Lupus, inflammatory bowel disease, severe arthritis and other inflammatory diseases Immunosuppressants such as cyclosporine, tacrolimus, azathioprine, or systemic steroids are currently being taken or planned during the study History of hereditary dyslipidemia such as familial hypercholesterolemia There has been a change in lipid regulation treatment within the past 1 month, or there is a current adjustment plan History of symptomatic non-traumatic cerebral hemorrhage at any time in the past History of gastrointestinal bleeding or major surgery within the past 6 months Use of Xuesaitong soft capsules or preparations containing the main ingredients of Xuesaitong in the past 1 month There were clear adverse reactions to the main components of Xuesaitong in the past Active liver disease, or alanine aminotransferase (ALT) levels > 3 times the upper limit of normal (ULN) Chronic kidney disease, or estimated glomerular filtration rate (eGFR) <60ml/ (min×1.73m2) Pregnancy or planned pregnancy, or breastfeeding Malignant tumors, or other serious diseases with an estimated survival of less than 1 year Mental disorders or communication disorders, cognitive impairment, or other serious medical conditions that may affect study participation Have participated in or are participating in other clinical trials within the last 1 month Poor adherence to follow-up or medication is known
引自 ClinicalTrials.gov, NCT06425120, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06425120,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。